Sexually transmitted infections returning to pre-pandemic levels in Rhode Island
HIV and other sexually transmitted infections (STIs) appear to be a slowly rising tide in the Ocean State, according to the most recent data from the state health department.
STI surveillance data is reported on a lag, so the March report issued by the Rhode Island Department of Health (RIDOH) contains long- and short-term data ending in 2023, plus some tentative findings for 2024. But recent increases in infections could also be trends returning to their baseline prior to the pandemic.
'If you look at the data starting in 2020 we did see some significant declines starting with the pandemic, and that is because we were seeing less testing, less healthcare visits,' said Dr. Philip Chan, a primary care physician with Brown University Health and a medical consultant on the RIDOH report.
But people's behavior also changed during that time, Chan added. 'People were more likely to stay at home, more likely to isolate. What we were seeing on the ground was that a lot of people had a lot less sex partners, so there was just a lot less sex going on.'
The good news is that the state usually succeeds in treating HIV, with outcomes more positive than national averages and patients' illness often stops before the virus progresses into AIDS. Less ideal are higher rates for other STIs like syphilis and gonorrhea, which climbed past pre-pandemic levels in 2023.
'From year to year, it's tough to tell exactly what's happening,' Chan said. 'But I think that the trends the last couple years are clear that things are going up.'
Data for the more ubiquitous infections includes:
Syphilis has increased 58% from 2014 to 2023. There were 328 cases recorded in 2021, the highest number in decades. That fell to 240 cases in 2022, and 190 in 2023 — about the same as pre-pandemic levels, which had already risen since 2014. Preliminary data for 2024 shows similar trends. From 2020 to 2023, there were also about 10 cases of congenital syphilis — the state's first instances in about a decade, and one example of testing's importance in early detection, Chan said.
Gonorrhea cases rose 183.4% over the last 10 years. There were 590 cases in 2014, compared to 1,672 cases in 2023. There has not been a year with fewer than 1,000 cases since 2016. Men account for about twice as many cases as women.
Chlamydia cases have remained more consistent since 2014, and rose 21% over the decade, from 4,349 cases in 2014 to 5,269 cases in 2023. Women ages 20-24 exhibited the highest increase over that same period, but the report notes that women access routine screenings more than men, who are often asymptomatic when infected.
'A key theme for all these STIs is that most people may not have symptoms,' Chan said. 'And so the only way that you know that you may have it is to get tested, and that's why testing is so so important.'
Chan pointed to primary care doctors and sex education as two ways people can become educated about the necessity of screening. Only 52% of adults ages 18 to 64 who had multiple sex partners received an STI test in the past year, according to 2022 data. Only 60% had ever received an HIV test.
What we were seeing on the ground was that a lot of people had a lot less sex partners, so there was just a lot less sex going on.
– Dr. Philip Chan, primary care physician and medical consultant for RIDOH STI surveillance report
Demographic and geographic factors also shaped the data. Racial disparities exist: In 2023, HIV rates were four times higher among Black residents and nearly sevenfold higher among Rhode Island's Latino population, compared to caucasian residents. New HIV cases among Latinos have risen 132% since 2019, while dropping 63% among Black Rhode Islanders. Of newly diagnosed HIV cases in 2023, 31% were diagnosed in people born outside the United States, most frequently in the Caribbean and Central and South America.
Younger people ages 15-24 account for most new STI diagnoses, about half. The state's urban core of Providence, East Providence, North Providence, Pawtucket, Woonsocket, Central Falls, and Cranston consistently reports the highest STI rates, with cases numbering in the dozens to hundreds, compared to fewer than five reported cases in many smaller towns.
'A lot of these STIs do disproportionately affect communities of color and other sorts of underserved populations,' Chan said. 'It's important, from a public health perspective, to think about how to continue and promote and increase access to care for those groups in order to address disparities like we see in STIs and frankly, many other things.'
While an assortment of drugs can stop bacterial infections, there's no cure for HIV. But HIV-positive people are living longer than ever due to modern antiretroviral drugs that suppress the virus and prevent it from progressing to a more serious diagnosis of AIDS. An adequately suppressed viral load can also make the disease intransmissible, and greatly improves quality of life by halting the virus from replicating. Advances in HIV drug therapy largely account for the deep reduction in the rate of HIV-related deaths, which nationally fell by almost half from from 2010 to 2017.
In Rhode Island in 2022, 93.2% of people living with HIV knew their status, 76% were receiving treatment and 71% had achieved viral suppression. And 93% of people who received their medical care within Rhode Island achieved viral suppression.
Still, there was an above average number of HIV diagnoses, the preliminary 2024 data showed. From 2019-2023, RIDOH also observed that about 20% of people newly diagnosed with HIV had progressed to stage 3, or AIDS. On average, it takes eight years for HIV to develop into AIDS.
Rhode Island has tried to prevent those outcomes by early diagnosis, and by fortifying its residents against HIV through preventative measures — namely, PrEP, or pre-exposure prophylaxis. Patients who adhere to the schedule for taking this group of antiretroviral drugs can have up to a 99% lower chance of contracting HIV from unprotected sex. PrEP provides an approximate 74% reduction in the likelihood of contracting HIV via injectable drug use.
Successful state laws from 2023 and 2024 made PrEP as widely available as possible by slashing away potential restrictions from insurers and eliminating out-of-pocket costs. Chan, only had 'good things to say' about those laws — including the resulting interactions with insurers, who have largely been quick to correct mistakes in patient billing. The main challenge now, Chan said, is when interruptions occur, and a person loses their job, insurance, and access to PrEP.
Several sexual health clinics and community health centers in Rhode Island offer low or no cost services and assist in minimizing any out-of-pocket costs associated with PrEP prescriptions and testing. For a list go to Rhode Island's PrEP Champions Network.
'I actually had a patient of mine for several years who had insurance and was on PrEP,' Chan said. 'They lost their insurance for a couple months and had to go off PrEP, and they actually, unfortunately, acquired HIV during that time. This was just a month ago.'
RIDOH continues to promote the Rhode Island PrEP Champions Network, which has participating clinics across the state that expedite access to PrEP as well as its sibling PEP, or post-exposure prophylaxis, which is taken for about a month, starting within 72 hours of possible HIV exposure. Properly taken, the drug prevents HIV infection.
The comparable treatment for preventing bacterial STIs is DoxyPEP, which usually consists of a single, two-pill, dose of doxycycline taken after sex. Doxycycline is an old drug, and thus an inexpensive means of lowering contraction rates, Chan suggested.
'DoxyPEP is the newest kid on the block,' he said, noting that the nationwide rollout is still in its early stages. But so far the data looks good, with evidence from places like San Francisco suggesting it can make a difference.
'We're very optimistic about it, and I think the coming years will be able to tell whether or not it's making a significant impact on overall population trends,' Chan said.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Post
an hour ago
- New York Post
Weed can help your migraines, says new study — if you use it the right way
High hopes for headache relief. A landmark new study suggests that inhaling a precise blend of CBD and THC can provide fast, meaningful relief from migraines. The research — presented at the American Headache Society (AHS) Annual Meeting 2025 — is the first of its kind. 4 The research — presented at the American Headache Society (AHS) Annual Meeting 2025 — is the first of its kind. Kateryna – 'This is the first placebo-controlled study in this space,' Dr. Nathaniel M. Schuster, a pain and headache neurologist and associate professor of anesthesiology at the UC San Diego (UCSD) Health Center for Pain Medicine, told Medscape Medical News. 'It's the first real — to me — compelling evidence for the antimigraine effects of cannabis in humans.' Scientists provided 92 patients — mostly women, with an average age of 41 — a treatment of 6% THC, 11% CBD, a combination of 6% THC and 11% CBD or a placebo. Roughly 67.2% in the THC/CBD group reported pain relief at 2 hours, compared to 46.6% in the placebo group. And approximately 34.5% of patients in the THC/CBD group achieved 'pain freedom' within that timeframe, compared to 15.5% in the placebo group. Patients also reported sustained pain relief up to 24 hours and most bothersome symptom freedom lasted through 48 hours. 4 'It's the first real — to me — compelling evidence for the antimigraine effects of cannabis in humans,' Schuster said. ststoev – Best of all: there were no serious side effects, although people in the THC-only group definitely got a little more high. 'It's known that CBD is a noncompetitive, negative allosteric modulator of the CB-1 [cannabinoid receptor 1] receptor that decreases the psychoactive side effects of the THC,' Schuster said. It's a big win for weed but, before you get rolling, Schuster noted that the patients received very controlled doses. 'A lot of neurologists, myself included, suspect that there could be medication overuse headache with [using] cannabinoids frequently,' he said. 'When I counsel patients now, I say, 'Look, we were only studying infrequent — four times over the course of a year — administration.'' 4 'A lot of neurologists, myself included, suspect that there could be medication overuse headache with [using] cannabinoids frequently,' he said. Africa Studio – He encouraged patients to limit the treatment to under 10 times per month and to 'optimally be using it really for those migraines that would not respond to standard-of-care therapy.' Weed has skyrocketed in popularity since 38 states and DC have legalized it for medical use. Of those, 24 states and DC have also cleared the way for adults 21 and over to use it recreationally. Research suggests that marijuana has the potential to ease chronic pain and reduce muscle spasms and stiffness linked to MS. Cannabis products have also been shown to boost appetite in HIV/AIDS and cancer patients, and combat chemo-related nausea. 4 Weed has skyrocketed in popularity since 38 states and DC have legalized it for medical use. Of those, 24 states and DC have also cleared the way for adults 21 and over to use it recreationally. amenic181 – Other potential benefits include easing stress, alleviating PTSD symptoms and aiding sleep in some people. However, mounting evidence does suggest it can pose risks to your heart, with one recent study showing marijuana has as much of a negative impact on cardiovascular health as tobacco — even if you don't smoke. Another recent study suggests that cannabis use raises the risk of heart attack and stroke more than cocaine, while other research claims it's sending older people to the hospital. Shockingly, scientists have also found that people with cannabis use disorder — that is, using weed enough that it causes problems and impairs your life — have altered dopamine activity in the brain that closely resembles patterns observed in psychosis. 'The biggest problem is that ever since it was made a Schedule 1 narcotic [in 1970], it has made it very difficult to do really well-devised, double-blind, placebo-controlled studies,' Dr. Ken Weinberg, chief medical officer of Cannabis Doctors of New York, previously told The Post. 'I don't think there's enough data.'
Yahoo
3 days ago
- Yahoo
U.S. program to combat HIV/AIDS survives Trump's latest round of cuts
WASHINGTON — PEPFAR, the popular global HIV/AIDS program credited with saving millions of lives, has been spared from a package of billions of dollars in spending cuts that Congress sent to President Donald Trump early Friday morning to sign into law. The original rescissions package Trump requested called for $400 million in cuts to PEPFAR, the President's Emergency Plan for AIDS Relief, which George W. Bush started in 2003. But in the Senate, Democrats and a handful of Republicans objected to the PEPFAR cuts. Appropriations Committee Chairwoman Susan Collins, R-Maine, said the health program had saved an estimated 26 million lives and allowed nearly 8 million babies to be born healthy to mothers living with HIV. "There are some cuts that I can support, but I'm not going to vote to cut global health programs," Collins told reporters last week. Seeking to tamp down the GOP rebellion, the White House this week agreed to make changes to the package, dropping the PEPFAR cuts to secure GOP votes. 'PEPFAR will not be impacted by the rescissions," White House budget director Russell Vought told reporters after he huddled behind closed doors Tuesday with Senate Republicans. Removing those cuts, Vought said, means the package has 'a good chance of passing.' The rescissions package, which would claw back $9 billion in congressionally approved funding for foreign aid and public broadcasting, narrowly passed the Senate early Thursday on a 51-48 vote. Collins was one of two Republicans to vote against the package, lamenting that the White House had not provided details of the cuts and that 'nobody really knows what program reductions are in it.' The House passed the package of cuts early Friday and Trump has vowed to sign it into law. The White House's original rescissions request sent May 28 detailed that the cuts would target only HIV/AIDS programs that "neither provide life-saving treatment nor support American interests." "This rescission proposal aligns with the Administration's efforts to eliminate wasteful foreign assistance programs," the request said. "Enacting the rescission would restore focus on health and life spending. This best serves the American taxpayer." But even some deficit hawks in the House said they supported the decision to preserve PEPFAR funding. "It's very successful. I think it serves a useful purpose," said conservative Rep. Gary Palmer, R-Ala., who voted for the rescissions package. Rep. Tim Burchett, R-Tenn., a member of the Foreign Affairs Committee who also supported the package, said, "It's half the money we've given to Ukraine, and it's saved 25 million lives." Senate Minority Leader Chuck Schumer, D-N.Y., slammed the legislation and said the PEPFAR-related changes were insufficient. 'Cuts to foreign aid will make Americans less safe. It will empower our adversaries,' he said. 'The changes Republicans say they've made to PEPFAR are not enough, and nobody's fooled by small tweaks to this package.' Some advocates were relieved by the removal of PEPFAR cuts but disappointed with the overall package. 'It is always good news when lawmakers prioritize children, especially children who are orphaned or vulnerable to HIV and AIDS. But the larger trend here is not hopeful," said Bruce Lesley, the president of First Focus Campaign for Children. 'While a few senators persuaded their colleagues to preserve funding for these children in this case," he said in a statement, "the Senate's overall decision to hand $9 billion back to the President suggests that what the legislature does actually doesn't matter.' This article was originally published on
Yahoo
3 days ago
- Yahoo
Abbott lowers sales forecast on diagnostics decline, US funding cuts
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers Q2 revenue: $11.14 billion 7.4% increase year over year Medical device sales: $5.37 billion 13.4% increase year over year Diagnostics sales: $2.17 billion 1% decrease year over year Abbott lowered its sales forecast for the year, citing a drop in diagnostic testing. CEO Robert Ford told investors on Thursday that the company is seeing a drop-off in COVID-19 testing sales, challenges in China's core laboratory market and a reduction in U.S. foreign aid funding for HIV testing, with a combined impact of more than $1 billion. The company reduced its 2025 organic sales growth forecast to a range of 6% to 7%, from the previous forecast of 7.5% to 8.5% shared in the first quarter. 'Even with that billion dollars, we're still forecasting high single-digit growth and absorbing the impact of tariffs,' Ford said. The company now expects 'just under $200 million' of impact from tariffs. CFO Phil Boudreau said the amount was down from previous estimates, when the company had outlined 'a few hundred million' in tariff costs. Discussing how the company plans to mitigate tariffs, Ford said that Abbott plans to open a new cardiovascular manufacturing facility in Georgia in 2028. 'Once tariffs get set in place, they're very difficult to walk away from,' the CEO said, 'so we have to think medium term, but also long term.' Growth in medical devices, diabetes A bright spot for Abbott was its medical device segment, which grew by more than 13% to $5.37 billion in sales. The company's diabetes segment grew by more than 20% to $1.98 billion. Analysts asked about Abbott's plans for a dual analyte sensor that would provide glucose and ketone readings. The company recently showcased the device during the American Diabetes Association's Scientific Sessions. Ford declined to provide a timeline or pricing details for the planned device. BTIG analyst Marie Thibault wrote in June that Abbott's management expects a launch sometime next year. The company is also partnering with insulin pump companies, including Tandem, Sequel Med Tech and Beta Bionics, to support the new sensor. 'I think this is going to be a real next-level, significant change in the CGM market,' Ford said, specifically for intensive insulin users. Abbott's electrophysiology business, with the company's new Volt pulsed field ablation device to treat cardiac arrhythmias, grew by 11.5% to $700 million. Recommended Reading 'We are not rolling over': J&J electrophysiology unit rebounds amid PFA rivalry Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data